BioPharmSignal logoBioPharmSignal

Biotech News

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Earnings

– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise – – Global Sephience™ (sepiapterin) launch momentum continues with first quarter 2026 revenue of $125 million, representing 36% quarter-over-quarter growth –

Open original release

Related news

PTCTPTC Therapeutics, Inc.2026-02-19 21:01 EST

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

PTCTPTC Therapeutics, Inc.2026-04-22 12:00 EST

PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

CAPRCapricor Therapeutics2026-05-12 20:05 EST

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

CAPRCapricor Therapeutics2026-05-04 20:05 EST

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

ABEOAbeona Therapeutics2025-11-12 12:30 EST

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

MNPRMonopar2026-05-14 18:00 EST

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

TARAProtara Therapeutics2026-05-13 12:00 EST

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

ABEOAbeona Therapeutics2026-05-04 12:30 EST

Abeona Therapeutics® Announces Date of First Quarter Financial Results

TARAProtara Therapeutics2026-03-10 12:00 EST

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

MNPRMonopar2025-11-13 13:00 EST

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

View all latest news

PTC Therapeutics, Inc.

PTC Therapeutics is a biopharmaceutical company focused on rare disease and gene-related therapies. Its story combines commercial products with a pipeline aimed at genetically defined conditions.

Recent company news

PTCTPTC Therapeutics, Inc.2026-05-07 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-05-04 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-04-28 20:05 EST

PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam

PTCTPTC Therapeutics, Inc.2026-04-28 13:28 EST

PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study

PTCTPTC Therapeutics, Inc.2026-04-22 12:00 EST

PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026

Stock data

Close
75.80 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States